Innate Pharma S.A. (EPA:IPH)
France · Delayed Price · Currency is EUR 1.908
+0.128 (7.19%)
Aug 21, 2026, 5:35 PM CET
Innate Pharma Revenue
In the year 2025, Innate Pharma had annual revenue of 9.01M EUR, down -55.25%. Innate Pharma had revenue of 4.15M in the half year ending December 31, 2025, a decrease of -80.67%.
Revenue
9.01M
Revenue Growth
-55.25%
P/S Ratio
19.90
Revenue / Employee
54.91K
Employees
164
Market Cap
179.20M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.01M | -11.12M | -55.25% |
| Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
| Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
| Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
| Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
| Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
| Dec 31, 2019 | 85.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 142.94M |
| Cellectis | 55.86M |
| Fermentalg | 13.38M |
| Transgene | 7.21M |
| Sensorion | 5.81M |
| MaaT Pharma | 4.52M |
| ABIONYX Pharma | 4.06M |
| Adocia | 3.85M |
Innate Pharma News
- 6 days ago - Innate Pharma price target raised to $9 from $8 at BTIG - TheFly
- 8 days ago - Innate Pharma SA To Hold Conference Call Transcript - GuruFocus
- 8 days ago - Innate Pharma Secures €30M, Extends Cash Runway Into 2028 - MarketBeat
- 9 days ago - Innate Pharma Transcript: Investor update - Transcripts
- 9 days ago - Innate Pharma Press release: Investor update - Filings
- 9 days ago - Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast - Finanz Nachrichten
- 9 days ago - Innate Pharma Announces Conference Call and Webcast - Business Wire
- 9 days ago - Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares - Wallstreet:Online